To read the full story, subscribe or sign in.

Roche presents novel P2X2 and P2X2/3 receptor antagonists

July 21, 2009

No Comments

BioWorld Science Neurology/psychiatric Patents

Today's news in brief

BioWorld

BioWorld briefs for Nov. 28, 2023.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November, 28 2023.

Aurinia Therapeutics’ AUR-300 proven useful in systemic sclerosis

BioWorld Science

Aurinia Pharmaceuticals Inc. has investigated their CD206 ligand AUR-300 as a novel therapeutic agent for systemic sclerosis treatment.

Alkermes spinout Mural Oncology launches with lead IL-2 drug

BioWorld

A year after Alkermes plc announced it would divide its oncology and neuroscience efforts into two separate businesses, the Dublin-based company spun out Mural...

Historic MHRA exa-cel win bagged, Crispr/Vertex await FDA nod

BioWorld

With a landmark U.K. approval in hand for Casgevy (exagamglogene autotemcel [exa-cel]) to treat sickle cell disease and transfusion-dependent beta thalassemia,...

Upgrade your daily dose of biopharma and medtech news

Roche presents novel P2X2 and P2X2/3 receptor antagonists